ICT announces $28.3M series B round

Innovative Cellular Therapeutics Co. Ltd. (Shanghai, China) raised RMB180 million ($28.3 million) in a series B round led by Volcanic Ventures and GTJA Investment Group, with participation from SBCVC, Dunhou Capital and Witruth Capital.

The company said its CD19-targeted CAR T cell candidate has led to a complete remission rate of 84.6% in clinical testing for advanced acute lymphoblastic leukemia (ALL). ICT also said it has a CAR T candidate in clinical testing to treat solid tumors, including breast cancer and pancreatic cancer. The company did not respond to inquiries...